LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

OBJECTIVE: A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). METHODS: LY3298176 is a fatty acid modified peptide wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Coskun, Tamer, Sloop, Kyle W., Loghin, Corina, Alsina-Fernandez, Jorge, Urva, Shweta, Bokvist, Krister B., Cui, Xuewei, Briere, Daniel A., Cabrera, Over, Roell, William C., Kuchibhotla, Uma, Moyers, Julie S., Benson, Charles T., Gimeno, Ruth E., D'Alessio, David A., Haupt, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308032/
https://www.ncbi.nlm.nih.gov/pubmed/30473097
http://dx.doi.org/10.1016/j.molmet.2018.09.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308032/
https://www.ncbi.nlm.nih.gov/pubmed/30473097
http://dx.doi.org/10.1016/j.molmet.2018.09.009

Ejemplares similares